ORIGINAL RESEARCH
Accepted on 23 Oct 2025
Efficacy and Safety of Apatinib or Anlotinib Combined with PD-1 Inhibitors-Based Therapy as Subsequent-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Real-World Retrospective Study
doi 10.3389/fonc.2025.1624286